VXRT bull flag VXRT looks to forming a bullish flag. Should close by EOD 6/25. Fibonacci retracement 50% holding. Longby richOFFpinkSHEETS7711
Bullish above $2.50Please note: just sharing my view. its not a recommendation for buying or selling.Longby MrMercatoUpdated 8
VXRT Vaxart with a ways to run before top of channelEspecially bullish in COVID timesLongby altinAdam8
Something to watch. Another high risk potentially high reward. If this falls below the 20 ema tomorrow. I’d expect to see some resistance between 2.40 and 2.00 This may bounce off the 20 ema tomorrow. We shall see. Honestly since this is in the bio sector I’m pretty skittish on this one. I picked mitt last week as a financial swing and that worked out nicely. Check my analysis on it. That run may not be over yet, but I’m out of it for now. The price predictions are based upon the respect for the weekly 20ema and the fibs and pivots. Just something I’m watching at the moment. I may buy in. Just a reminder. I’m not a pro and my style is based upon Shorter term swing trading. 1-5 day holds by ebred3
VXRT diagonal issuesStay alert here, trending below diagonal support on short time frames, needs to stay above otherwise large short is likely. I personally will sell on confirmation of break of support. Otherwise holding. Not financial advice, just what I am doing.by Win2196
VXRT longTrump kind of threw a blow to all vaccine companies other than the 5 he mentioned as most likely to succeed, but VXRT is on two different diagonal support lines. Small position here, but know that if it breaks below the trendlines it will not look great. Longby Win2197
VXRT longDiagonal support maintained, diagonal resistance broken and retested. I’m long.Longby Win21910
VXRT - Long or Hold for Cup and Handle - BullishChart tells you everything you need to know. News makes me thing it could break now vs cup and handle. Either way its a hold.Longby DigitalData6610
VXRT - Big Moves AheadAll, This may drop to $2.30-2.50 but after that should be a move up. We are moving into a previous consolidation area. The news etc outlook prior to the virus all look like it should move up. However, you never know so keep an eye out of course. We should see some movement this week for sure.Longby DigitalData6
VXRT Short - Bad bet on CoronaAside from the short term stimulus in the headlines, there is really no upside in product pipeline. The stock itself looks to be developing a HS pattern. Will probably be heading down in the short term. Consolidate in the mid term. Heading lower in the long term. This is assuming it has no major development in its products. Recipe for investment destruction.Shortby Tear6rop337
$VXRT on alert for breakoutBiotech Vaxart (VXRT) has announced positive pre-clinical results for its oral COVID-19 vaccine candidates, with several of the vaccine candidates generating immune responses in all tested animals after a single dose. Shares have surged 35% in pre-market trading Tuesday, with the stock’s year-to-date gain already at an eye-watering 567%. “These early pre-clinical results are in line with those for our oral influenza vaccine which was protective in a clinical Phase 2 efficacy study,” said Sean Tucker, Ph.D., CSO of Vaxart, adding that additional data will inform which candidate moves forward into clinical trials. Source smarteranalysis by DEXWireNews20
$VXRT bullish on Data Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has obtained positive pre-clinical results for its COVID-19 vaccine candidates, with several of the vaccine candidates generating immune responses in all tested animals after a single dose. “These early pre-clinical results are in line with those for our oral influenza vaccine which was protective in a clinical Phase 2 efficacy study,” said Sean Tucker, Ph.D., chief scientific officer of Vaxart. “Additional data will inform us on which candidate we will move forward into clinical trials. We are particularly interested in vaccine candidates that can generate mucosal immune responses in addition to serum antibody responses. That is a key feature of our oral vaccines and potentially significant for protection against SARS CoV-2, the virus that causes COVID-19.” Source Globalnewswire by RedHotStocks20
short ideainfo in the chart. of course it could break out and cause a squeeze but we are going with highest probability: Dump.Shortby NYBKLYN4
VAXART INC Approaching resistance | Price TargetsVaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. The company was founded in 2004 and is headquartered in South San Francisco, CA.by DEXWireNews15
VAXART - Coronavirus stockVaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. The company was founded in 2004 and is headquartered in South San Francisco, CA.Longby DEXWireNews12
Vaxart, Inc. Trend-line break possible Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. The company was founded in 2004 and is headquartered in South San Francisco, CA.Longby DEXWireNews16
VXRT Very Strong RunVXRT stock had a great run today due to positive news from their norovirus vaccine. Shs Float is at 3.96M and their market cap is 16.12M. We will be watching this for a continuation play tomorrow. Watch my full video review for $VXRT by using the link in my signature description!by TradeWithTyler1
Swallow your Flu shotYesterday positive results from phase 2 study of their oral vaccine against flu was released. Seeking alpha: The vaccine elicited a significant expansion of mucosal homing receptor alfa4beta7+ (beta7+) plasmablasts, cells that play a key role in an immune response, to about 60% of all activated B cells, significantly higher than 20% from Sanofi's (NYSE:SNY) Fluzone. FYI , SNY is 100B company.Longby tylenisbobas3